Recombinant Cynomolgus Monkey ALCAM His-tag Protein, CF

Catalog #: 10027-AL Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
10027-AL-100

Recombinant Cynomolgus Monkey ALCAM His-tag Protein Binding Activity

2 Images

Product Details

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Cynomolgus Monkey ALCAM His-tag Protein, CF Summary

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA. When Recombinant Human Cynomolgus Monkey ALCAM/CD166 is immobilized at 1 µg/mL (100 µL/well), Biotinylated Recombinant Human CD6 Fc Chimera binds with an ED₅₀ of 10-50 ng/mL.

Source

Chinese Hamster Ovary cell line, CHO-derived cynomolgus monkey ALCAM/CD166 protein
Trp28-Ala526, with a C-terminal 6-His tag

Accession #

XP_005548303

N-terminal Sequence
Analysis

Trp28

Predicted Molecular Mass

57 kDa

SDS-PAGE

67-89 kDa, reducing conditions

Product Datasheets

10027-AL

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

10027-AL

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 1 mg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, ≤ -20 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, ≤ -20 °C under sterile conditions after reconstitution.

Scientific Data

Binding Activity

View Larger

When Recombinant Cynomolgus Monkey ALCAM (Catalog # 10027-AL) is coated onto a microplate at 1 µg/mL, Biotinylated Recombinant Human CD6 Fc Chimera binds with an ED₅₀ of 10-50 ng/mL.

SDS-PAGE

View Larger

2 μg/lane of Recombinant Cynomolgus Monkey ALCAM/CD166 was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 67-89 kDa.

Reconstitution Calculator

Background: ALCAM/CD166

ALCAM (activated leukocyte cell adhesion molecule), designated CD166, is a 100‑110 kDa type I transmembrane glycoprotein and a member of the Ig CAM family within the immunoglobulin superfamily (1). The cynomologous ALCAM amino acid (aa) sequence includes a signal peptide, an extracellular domain (ECD) with two V‑type and three C2‑type Ig‑like domains, a transmembrane domain and a short cytoplasmic domain (1). Human ALCAM has several isoforms, including an isoform lacking most of the cytoplasmic domain and a secreted isoform (sALCAM) which antagonizes full‑length ALCAM (2, 3). Mature cynomologous ALCAM ECD shares 93% and 96% aa sequence identity with human and mouse/rat ALCAM, respectively. ALCAM is expressed on multiple cell types including thymic epithelium, microvascular endothelium, activated lymphocytes and monocytes, and monocyte‑derived dendritic cells (1, 4). ALCAM mediates low‑affinity adhesion with itself or the cysteine‑rich scavenger receptor CD6 to regulate T cell development, immunological synapses (IS), and cell migration through endothelial junctions (1‑11). ALCAM on thymic epithelia mediates adhesion to CD6 on CD4⁺CD8⁺ T cells (6). Adhesion of ALCAM‑expressing antigen presenting cells and CD6‑expressing T cells stabilizes the early IS, while later it enhances CD3 effects on T cell proliferation, CD25 expression, and Th1 commitment (4, 7, 8). High ALCAM expression at the blood‑brain barrier in active multiple sclerosis, and its mouse model (EAE), promotes leukocyte migration to the brain (8, 9). High ALCAM expression on melanoma cell lines appears to be pro‑metastatic, but anti‑metastatic activity has been reported in breast cancer (3, 10, 11). ALCAM may influence expression or adhesion of the neuronal adhesion molecule NCAM‑L1, both in the developing retina and invasive melanoma (2, 12).

References